| DIRECT COMPETITOR COMPARISON | |
| QDEL | BEC | Pvt1 | IMA | Industry | | Market Cap: | 387.68M | 4.53B | N/A | 3.47B | 62.33M | | Employees: | 322 | 11,000 | N/A | 8,300 | 56 | | Qtrly Rev Growth (yoy): | 76.20% | 8.40% | N/A | 22.10% | 18.90% | | Revenue (ttm): | 131.17M | 3.08B | N/A | 1.90B | 12.73M | | Gross Margin (ttm): | 61.93% | 47.09% | N/A | 53.81% | 50.63% | | EBITDA (ttm): | 38.56M | 665.30M | N/A | 475.37M | -1.76M | | Oper Margins (ttm): | 24.10% | 12.40% | N/A | 9.24% | -19.80% | | Net Income (ttm): | 18.85M | 166.00M | N/A | 24.80M | N/A | | EPS (ttm): | 0.608 | 2.532 | N/A | 0.308 | N/A | | P/E (ttm): | 21.15 | 25.80 | N/A | 135.55 | 23.64 | | PEG (5 yr expected): | 0.94 | 1.47 | N/A | 0.91 | 1.36 | | P/S (ttm): | 2.98 | 1.49 | N/A | 1.84 | 3.09 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BEC | | Beckman Coulter to lay off 11 from Webster plant
Tue, Nov 24 -
at bizjournals.com | | • | BEC | | Experienced Asset Manager Reveals Key Exit Trigger For Portfolio Holdings
Tue, Nov 24 -
Wall Street Transcript | | • | BEC | | Beckman Coulter to Present at the 2009 Piper Jaffray Healthcare Conference
Mon, Nov 23 -
PR Newswire | | • | IMA | | To Manage Weight Over the Holidays, Experts From Alere Say Enjoy, Indulge a Little and Don't Diet!
Mon, Nov 23 -
PR Newswire | | • | BEC | | 4-Star Stocks Poised to Pop: Sequenom
Mon, Nov 23 -
at Motley Fool | | • | IMA | | OraSure settles HIV test patent lawsuit
Thu, Nov 19 -
AP | | • | IMA | | Alere Secures Prestigious NCQA Accreditation for Wellness & Health Promotion
Thu, Nov 19 -
PR Newswire | | • | IMA | | American Funds' Achilles' Heel
Tue, Nov 17 -
at Motley Fool | | • | IMA | | [video] Trading Higher in a Down Market
Tue, Nov 17 -
at TheStreet.com | | • | BEC | | BECKMAN COULTER INC Financials
Wed, Nov 11 -
EDGAR Online Financials | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
